MannKind Corporation

NasdaqGM:MNKD Lagerbericht

Marktkapitalisierung: US$1.9b

MannKind Management

Management Kriterienprüfungen 3/4

MannKind CEO ist Michael Castagna , ernannt in May 2017, hat eine Amtszeit von 7.5 Jahren. Die jährliche Gesamtvergütung beträgt $7.07M , bestehend aus 9.9% Gehalt und 90.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.83% der Aktien des Unternehmens, im Wert von $15.60M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.3 Jahre bzw. 4.8 Jahre.

Wichtige Informationen

Michael Castagna

Geschäftsführender

US$7.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts9.9%
Amtszeit als Geschäftsführer7.5yrs
Eigentum des Geschäftsführers0.8%
Durchschnittliche Amtszeit des Managements7.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Michael Castagna im Vergleich zu den Einnahmen von MannKind verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$22m

Jun 30 2024n/an/a

US$12m

Mar 31 2024n/an/a

US$8m

Dec 31 2023US$7mUS$702k

-US$12m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$4mUS$623k

-US$87m

Sep 30 2022n/an/a

-US$98m

Jun 30 2022n/an/a

-US$88m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$4mUS$598k

-US$81m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$4mUS$495k

-US$57m

Sep 30 2020n/an/a

-US$45m

Jun 30 2020n/an/a

-US$44m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$2mUS$511k

-US$52m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$61m

Mar 31 2019n/an/a

-US$71m

Dec 31 2018US$2mUS$500k

-US$87m

Sep 30 2018n/an/a

-US$110m

Jun 30 2018n/an/a

-US$119m

Mar 31 2018n/an/a

-US$131m

Dec 31 2017US$1mUS$459k

-US$117m

Vergütung im Vergleich zum Markt: MichaelDie Gesamtvergütung ($USD7.07M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.34M).

Entschädigung vs. Einkommen: MichaelDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Michael Castagna (47 yo)

7.5yrs

Amtszeit

US$7,068,114

Vergütung

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Lauren Sabella
Chief Operating Officer1.7yrsUS$2.74m0.025%
$ 478.2k
David Thomson
Executive VP22.8yrsUS$2.34m0.17%
$ 3.1m
Stuart Tross
Executive VP and Chief People & Workplace Officer7.9yrsUS$2.22m0.22%
$ 4.1m
Christopher Prentiss
Chief Financial Officerless than a yearkeine Datenkeine Daten
Sanjay Singh
Executive Vice President of Technical Operations2.1yrsUS$1.12m0.035%
$ 650.2k
Rosabel Alinaya
VP of Investor Relations & Treasury7.3yrsUS$519.59kkeine Daten
John Bedard
Senior Vice President of Worldwide Regulatory Affairs19.1yrskeine Datenkeine Daten
James McCauley
Chief Commercial Officer7.3yrsUS$921.51kkeine Daten
Burkhard Blank
Executive VP of Research & Development and Chief Medical Officer1.5yrskeine Daten0.070%
$ 1.3m

7.3yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: MNKDDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.3 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Michael Castagna
CEO & Director7.5yrsUS$7.07m0.83%
$ 15.6m
Ronald Consiglio
Independent Director21.1yrsUS$241.73k0.043%
$ 805.2k
Kent Kresa
Chairman Emeritusless than a yearUS$240.64k0.096%
$ 1.8m
Christine Ann Mundkur
Independent Director6yrsUS$226.73k0.010%
$ 188.3k
Michael Friedman
Independent Director20.9yrsUS$229.23k0.0054%
$ 101.6k
Anthony Hooper
Independent Director4.8yrsUS$233.14k0.064%
$ 1.2m
James Shannon
Independent Chairman9.5yrsUS$255.64k0.0089%
$ 166.3k
Sabrina Kay
Independent Director3.9yrsUS$221.73k0.039%
$ 727.8k
Thomas Blevins
Member of Scientific Advisory Board3.3yrskeine Datenkeine Daten
Steven Binder
Directorless than a yearUS$2.34m0.20%
$ 3.7m
Jennifer Grancio
Independent Director4.7yrsUS$221.73k0.040%
$ 752.7k
Davida Kruger
Member of Scientific Advisory Board3.3yrskeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

64.5yo

Durchschnittliches Alter

Erfahrener Vorstand: MNKDDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).